ArticleTherapeutic advances in medical oncology2025
Pan-immune-inflammation value as a novel predictor of pathological response to neoadjuvant chemotherapy combined with anti-PD-1 therapy in esophageal squamous cell carcinoma: a multicenter real-world retrospective clinical study.
Article in Therapeutic advances in medical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Exploratory analysis of serial pan-immune-inflammation value and its early dynamics during neoadjuvant chemotherapy as a predictor of complete cytoreduction at interval debulking surgery in advanced ovarian cancer: a retrospective cohort study.World journal of surgical oncology · 2026Article
- Human lncRNA, hLinfRNA7 (IDO1-AS) Regulates Cytokine Expression, Tryptophan Catabolism, and Inflammatory Response in Macrophage.Molecular and cellular biology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Current biomarkers for predicting pathological response to neoadjuvant chemoimmunotherapy in esophageal squamous cell carcinoma (ESCC) remain limited. Objective: This study investigates the potential of the pan-immune-inflammation value (PIV) as a biomarker for predicting pathological response after neoadjuvant chemoradiotherapy combined with anti-programmed death protein-1 (PD-1) therapy in ESCC. Design: A multicenter, real-world, retrospective clinical study conducted across five centers in Southern China (January 2021-March 2024). Methods: A multicenter retrospective study included 334 patients with ESCC, divided into pathological complete response (pCR) and non-pathological complete response (non-pCR) groups. Clinical and laboratory data were analyzed using univariate and multivariate logistic regression to evaluate the relationship between post-treatment PIV and pathological response. The threshold effect of PIV was explored using restricted cubic spline analysis. Results: Subgroup analysis showed no significant interactions across clinical subgroups. Post-treatment PIV was positively associated with non-pCR risk (odds ratio = 1.002; 95% confidence interval: 1.001-1.003, Conclusion: Post-treatment PIV shows a nonlinear relationship with pathological response in patients receiving neoadjuvant chemoradiotherapy combined with anti-PD-1 therapy and may serve as a predictive biomarker.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.